Patents by Inventor Marlon F. Levy

Marlon F. Levy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10758551
    Abstract: It was discovered that NF-?B signaling pathway plays a central role in pancreatitis, and inhibition of NF-?B signaling has the potential to reduce the incidence of pancreatitis and protect pancreatic tissues from inflammatory damage. Aspects of the disclosure relate to a method for inhibiting or treating pancreatitis in a subject in need thereof comprising administering a therapeutically effective amount of an NF-?B signaling pathway inhibitor to the subject.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: September 1, 2020
    Assignee: Baylor Research Institute
    Inventors: Mazhar Adnan Kanak, Bashoo Naziruddin, Marlon F. Levy
  • Publication number: 20180117067
    Abstract: It was discovered that NF-?B signaling pathway plays a central role in pancreatitis, and inhibition of NF-?B signaling has the potential to reduce the incidence of pancreatitis and protect pancreatic tissues from inflammatory damage. Aspects of the disclosure relate to a method for inhibiting or treating pancreatitis in a subject in need thereof comprising administering a therapeutically effective amount of an NF-?B signaling pathway inhibitor to the subject.
    Type: Application
    Filed: March 30, 2016
    Publication date: May 3, 2018
    Inventors: Mazhar Adnan KANAK, Bashoo NAZIRUDDIN, Marlon F. Levy
  • Patent number: 8637494
    Abstract: Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from Withania somnifera to effectively block NF-kB activation in beta cells, minimize cytokine-induced cell death and improve survival of transplanted islets. The method of the present invention involves identifying a subject having islet cells in need of treatment; and providing a effective amount of a Withaferin A composition disposed in a pharmaceutically acceptable carrier in an amount sufficient to reduce the inflammation after cytokine exposure without affecting the viability and potency of the islet cell population.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: January 28, 2014
    Assignee: Baylor Research Institute
    Inventors: Bashoo Naziruddin, Han Peng, Shinichi Matsumoto, Marlon F. Levy
  • Publication number: 20120135015
    Abstract: Methods for generating pancreatic stem cells from a pancreatic tissue of 24-week old mice by transient overexpression of reprogramming factors combined with Pdx1 selection is described herein. The generated cells were designated as iPaS (induced pancreatic stem) cells and exhibit the same morphology as the pancreatic stem cells previously established from young donors without genetic manipulation and express genetic markers of endoderm and pancreatic progenitors. Transplantation of the iPaS cells into nude mice resulted in no teratoma formation. Moreover, iPaS cells were able to differentiate into insulin-producing cells more efficiently than ES cells. In addition, the technology of transient overexpression of reprogramming factors and tissue-specific selection of the present invention may also be useful for the generation of other tissue-specific stem cells.
    Type: Application
    Filed: September 19, 2011
    Publication date: May 31, 2012
    Applicant: Baylor Research Institute
    Inventors: Hirofumi Noguchi, Marlon F. Levy, Shinichi Matsumoto
  • Publication number: 20110305719
    Abstract: Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from Withania somnifera to effectively block NF-kB activation in beta cells, minimize cytokine-induced cell death and improve survival of transplanted islets. The method of the present invention involves identifying a subject having islet cells in need of treatment; and providing a effective amount of a Withaferin A composition disposed in a pharmaceutically acceptable carrier in an amount sufficient to reduce the inflammation after cytokine exposure without affecting the viability and potency of the islet cell population.
    Type: Application
    Filed: June 14, 2011
    Publication date: December 15, 2011
    Applicant: Baylor Research Institute
    Inventors: Bashoo Naziruddin, Han Peng, Shinichi Matsumoto, Marlon F. Levy